DaVita Inc. (DVA) is a leading provider of dialysis services in the United States, serving more than 200,000 patients in over 2,700 outpatient dialysis centers nationwide. DaVita operates medical groups and affiliated physicians providing specialty services including nephrology, cardiology, and internal medicine.
Founded in 1994, DaVita, originally known as Total Renal Care Holdings, has its headquarters in Denver, Colorado. The name DaVita is derived from an Italian phrase, "dare vita," which translates to "giving life," reflecting the company's commitment to providing life-extending dialysis treatment to individuals with chronic kidney disease.
DaVita's primary operating division, DaVita Kidney Care, focuses on treating patients with end stage renal disease (ESRD), a condition that eventually requires dialysis or a kidney transplant. The company's services include in-center hemodialysis, peritoneal dialysis, home hemodialysis, vascular access management, chronic kidney disease education, and renal diet assistance.
Beyond dialysis services, DaVita also runs a network of comprehensive care clinics through its DaVita Medical Group. These clinics offer primary care and specialist services, integrated care management for individuals with significant chronic conditions, as well as interventions designed to address the social determinants of health.
DaVita's commitment to patient care extends into research as well; the company frequently collaborates with pharmaceutical and biotech companies to study and develop new treatments for kidney disease.
Furthermore, DaVita is deeply committed to social responsibility. Through the DaVita Way of Giving, the company's teammates, patients and physicians have contributed over $17 million to local non-profit organizations. Its Village Service Days encourage teammates to volunteer for events that support local communities.
In the stock market, DaVita Inc. trades under the ticker symbol DVA on the New York Stock Exchange. Its financial performance and commitment to improving quality of life for dialysis patients have made it a key player in the healthcare sector.
Through its innovative initiatives and leading healthcare provisions, DaVita has demonstrated its dedication to 'giving life.' The company's efforts continue to establish it as a premier provider of kidney care and a significant contributor to advancements in the healthcare industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
U.S. Physical Therapy (USPH) is scheduled to report earnings this Wednesday after market close. Analysts expect revenue to grow by 8.7% year-on-year, a slowdown from the 17.3% growth in the same quarter last year. The company has a history of rarely missing Wall Street's revenue estimates, and investor sentiment in the healthcare providers & services segment has been positive recently.
Valero Energy Corporation is acquiring LyondellBasell's former Houston Refinery site for $320.5 million and plans to restart 165,000 barrels per day of processing capacity by the end of 2027. This strategic acquisition expands Valero's Gulf Coast refining footprint amidst strong refining margins and aligns with broader U.S. administration efforts to boost domestic fuel capacity. The deal is expected to be accretive for Valero shareholders, providing low-cost capacity, while offering longer-term benefits for consumers through increased fuel supply.
Berkshire Hathaway shares reached new all-time highs despite a lackluster week, with Class A stock closing at a record $821,931 and Class B shares setting a new intraday record. The company's stock benefited from a "back-to-basics" rotation as money moved away from AI and tech stocks, resulting in an 8.9% gain for October. However, Berkshire's significant stake in Alphabet took a hit due to disappointing earnings and concerns about AI infrastructure costs, causing its value to drop by a quarter.
DaVita Inc. reported strong third-quarter 2026 results, with adjusted EPS of $3.82 and revenues of $3.58 billion, both surpassing analyst estimates. The growth was primarily driven by robust performance in Integrated Kidney Care (IKC) and international operations, alongside an increase in U.S. dialysis treatments. The company also narrowed its adjusted operating income and EPS guidance for 2026 while raising its IKC-adjusted operating income expectations.
DaVita Inc. reported a Q3 adjusted operating income of $561 million and adjusted EPS of $3.82, narrowing full-year guidance for adjusted operating income to $2.175 billion to $2.25 billion. The company is nationally rolling out Expanded HD dialyzers, anticipating significant patient care improvements and mortality rate reductions, with financial benefits expected in late 2028. Integrated Kidney Care performed well, increasing its adjusted operating income guidance to at least $65 million for 2026, supported by a new Humana partnership and improved savings rates.
Shares of DaVita Inc. (DVA) advanced 5.10% to $193.31 on Thursday, outperforming the broader stock market, which saw the S&P 500 Index and Dow Jones Industrial Average decline. This marks the second consecutive day of gains for DaVita's stock.